About anifrolumab
Type I interferon receptor-blocking monoclonal antibody
Used for
- Treats moderate-to-severe systemic lupus erythematosus in adults alongside standard therapy.
Usual adult dose
300 mg by intravenous infusion over 30 minutes every 4 weeks.
Common side effects
- Upper respiratory infections
- Bronchitis
- Infusion-related reactions
- Shingles
Important warnings
- Increases risk of infections, including shingles.
- Avoid starting treatment during an active infection.
- Live vaccines should be avoided during treatment.
- Not recommended for severe active lupus nephritis or severe central nervous system lupus.
Pregnancy
Human pregnancy data are limited; potential fetal harm is unknown. Use only when benefits outweigh risks.
Breastfeeding
It is unknown whether anifrolumab passes into breast milk; consider treatment benefits and breastfeeding needs.
Interactions
- Avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.